Unione Europea - italiano - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - pigs - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Unione Europea - italiano - EMA (European Medicines Agency)

fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - prodotti immunologici per leporidae - conigli - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

theramex ireland limited - ganirelix - ganirelix

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infezioni da virus respiratorio sinciziale - vaccini - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. vedi sezioni 4. 2 e 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali.